More Videos
SPECIAL REPORT
MOST SHARED
- Health-Care Reform Does Little To Contain Costs: Analysts
- Home Prices Sank Further In Most Parts of US in 3rd Quarter
- 'Peak Oil' Closer Than IEA Forecasts Show: Report
- News Corp. May Pull Content From Google Searches
- Jobless Rate to Hit 10.5%, Keeping Fed in Box: Poll
- If Mickey Mouse Has to Change—What Does That Say About You?
- Nov. 10: S&P Stocks Trading at New 52-Week Highs
- Treasurys Head Lower as Auction Fails to Impress
- America Is On Sale
- Trader Tax Sound Off
- Shadow Inventory Dwarfs Loan Mods
- The Lloyd's Prayer
- Playing Activision and Other Video Game Stocks: Analyst
- Expect 'At Least' Another 10-15% Upside: Fund Manager
- If Mickey Mouse Has to Change—What Does That Say About You?
- Nov. 10: S&P Stocks Trading at New 52-Week Highs
- Passive Job Search Strategies
- Back Off, Regulators!
- America Is On Sale
- Housing: 'Shadow Inventory' Dwarfs Loan Modifications
- Home Prices Decline Further In Most Parts of US
- UBS Faces Roadblock in Poaching More BofA Talent
- Jobless Rate to Hit 10.5%, Keeping Fed in Box: Poll
- Credit Card Firms Squeeze Customers as Rules Loom
- 'Thriller' Art: Warhol's Jackson Work Could Net $700,000
- Health Reform Does Little to Contains Costs: Analysts
- Ponzi Proceeds: Bidding on Madoff's Toys
- Quiz: Do You Know Your Coca-Cola Myths?
RSS FEED
Pharma's Market
Text Size 
 |
CNBC.com Pharma Stocks |
But there's enough gloom and doom out there so, I'm going to write about a little good news for a bunch of companies in the sector.
The journal "Science" is out with its annual ranking of the best biopharma employers. And Genentech has grabbed the top position again. It had been #1 for the first five years of the survey, but fell to #2 last year, behind Boehringer Ingelheim which dropped to #4 this year. As an aside, shares of DNA were briefly halted for trading this morning. According to Dow Jones it was due to an imbalance.
Our guy on the NYSE floor, Bob Pisani, told me there was some buzz about Roche having secured the financing to do the Genentech deal, but if that were the case wouldn't you think the stock would head in the other direction? Anyway, back to the survey.
Nearly 4,000 people took it in April and May of this year (long before Roche made a play for Genentech, so you can't argue this was a Genentech get-out-the-vote-to-show-how-special-we-really-are campaign). Thirty eight percent of them worked for biotech, 34 percent for pharma, 14 percent for biopharma and the rest in "other life sciences organizations". And they're highly educated and experienced.
Seventy percent had a Ph.D., MD or both. And almost two-thirds had been working in the industry for at least a decade. Sixty-two percent picked the company they work for as the best and they scored companies on nearly two dozen "driving characteristics." This year the top six "driving characteristics" are: 1. innovative leader in the industry, 2. social responsibility, 3. employee loyalty, 4. employer respect for employees, 5. leadership moving the company in the right direction (that one broke into the top six this year) and 6. work and personal values are aligned.
Peter Gwynne, who authored the piece wrote, "For the first time a company outside the mainstream pharmaceutical and biopharmaceutical business has reached the pinnacle of top employers." That'd be Monsanto which jumped from #8 in 2007 to #2 in 2008. The rest of the top 10 are Genzyme, the aforementioned Boehringer, followed by Schering-Plough, Roche, EMD Serono, Inc., Millennium (which has been bought by Japan's Takeda), Gilead Sciences, and Eli Lilly. LLY is so proud of breaking into the top tier that it put out a press release about it. Pfizer and Bristol-Myers Squibb are the only two big pharmas that didn't crack the top 20.
Update: AstraZeneca is no longer an exception. AZN has now joined the rest of the big pharma stocks touching new lows today.
Questions? Comments?
Data is a real-time snapshot *Data is delayed at least 15 minutes